Thanks to research, we now know more about triple negative breast cancer and are finding kinder and smarter ways to treat it.
The Catalyst Programme encompasses a number of research projects, all aiming to find preventions, treatments and cures for breast cancer. In this episode, we take a closer look into four of them.
Explore some of the genes and proteins our scientists study and how this knowledge can lead to new treatments.
New research has identified a new class of targeted cancer drugs that could be used to treat patients whose tumours have changes to the BRCA genes.
New research reveals the role a molecule called Endo180 plays in breast cancer spreading and becoming incurable.
After over a decade of work, Breast Cancer Now-funded researchers have found a new potential treatment option for women living with BRCA mutated secondary breast cancer. New research has now revealed that a one year course of this treatment can help to reduce the risk of breast cancer recurrence, and progression to secondary breast cancer, in people with early breast cancer with a change in the BRCA gene.
New research has revealed that a one year course of a drug called a PARP inhibitor can help to reduce the risk of breast cancer recurrence, and progression to secondary breast cancer, in people with early breast cancer with a change in the BRCA gene.
This week, we're taking a quick peek into the research side of things with our Research Communications Officer, Edd.
His Royal Highness met with researchers, donors and supporters to hear about our achievements and how the COVID-19 pandemic has impacted our funded research.